NEWS BRIEF: Legend Biotech’s revenue doubles on big gains for CAR-T treatment

LEGN.US

Cancer treatment maker Legend Biotech Corp. (LEGN.US) reported on Friday its revenue more than doubled to $187 million in the second quarter from $73 million a year earlier, while its loss also narrowed sharply to $18 million from $199 million. Most of its revenue came from sales of Carvykti, a chimeric antigen receptor T-cell (CAR-T) therapy to treat cancer.

“Momentum for Carvykti is growing,” said Legend CEO Huang Ying, commenting on the drug that has become Legend’s primary revenue source since its approval by the FDA in the U.S. in 2022. “We look forward to starting commercial production at our Obelisc facility in Belgium later this year in order to meet the growing demand, and we remain laser-focused on increasing our manufacturing capacity.”

, , , ,

Related Articles

RELATED ARTICLES

  1. Henlius Bio
    After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
    2696.HK
  2. Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  3. Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
  4. Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
    ZYBT.US
  5. Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  6. NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
    0013.HK HCM.US
  7. Yalla revenue growth returns to double-digits ahead of new gaming push
    YALA.US
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

New Oriental provides education services

New Oriental gets new lesson from souring U.S.-China relations

China’s leading private provider of education services blamed changing international relations for a slowdown in its business catering to students planning to study abroad Key Takeaways: New Oriental’s revenue from…
9901.HK EDU.US

BRIEF: Breton launches $30 million Hong Kong IPO

Construction machinery maker Breton Technology Co. Ltd. (1333.HK) launched its Hong Kong public offering Friday, announcing plans to sell 13 million shares for HK$18 apiece to raise HK$234 million ($30…
1333.HK